MoonLake Immunotherapeutics announced positive Week 16 results from its Phase 3 IZAR-1 trial of sonelokimab for psoriatic arthritis, meeting all primary and secondary endpoints. However, the company's stock fell over 8% in premarket trading. Investors expressed concern over how the drug's efficacy stacks up against UCB's approved biologic Bimzelx, alongside anxiety surrounding recent heavy insider selling by MoonLake executives.
IZAR-1 Phase 3 trial results
- ▪In the IZAR-1 trial, a 60 mg dose of sonelokimab with induction resulted in 42.1% of patients achieving an ACR50 response at Week 16.
- ▪In the IZAR-1 trial, 66.5% of patients achieved an ACR20 response, 41.2% reached minimal disease activity, and 61% of patients with skin involvement achieved a PASI90 response at Week 16.
- ▪The Phase 3 IZAR-1 trial remains blinded for comparative analyses versus placebo and will continue through Week 52, with full results expected in the first half of 2027.
- ▪MoonLake Immunotherapeutics announced that its Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve adults with active psoriatic arthritis met all primary and secondary clinical endpoints at Week 16.
Sonelokimab competitive positioning
- ▪Clear Street analyst Kaveri Pohlman stated that MoonLake Immunotherapeutics' trial data for sonelokimab was strong and largely matched results seen with UCB's FDA-approved biologic Bimzelx.
- ▪Clear Street analyst Kaveri Pohlman noted that the absence of a placebo arm in the initial IZAR-1 disclosure made it difficult to assess the magnitude of sonelokimab's benefit relative to placebo.
Stock price decline
- ▪MoonLake Immunotherapeutics' shares fell more than 8% in premarket trading on August 10, 2026, amid investor concerns regarding how sonelokimab compares to UCB's Bimzelx.
- ▪MoonLake Immunotherapeutics' stock price gapped down on August 10, 2026, opening at $17.24 after previously closing at $18.26.
Cash runway through mid-2028
- ▪MoonLake Immunotherapeutics expects its existing capital to fund operating expenses and capital requirements into mid-2028, with up to $400 million available under its Hercules Capital debt facility.
- ▪MoonLake Immunotherapeutics ended the second quarter of 2026 with $537 million in cash, cash equivalents, and short-term marketable debt securities.
Insider selling activity
- ▪MoonLake Immunotherapeutics insider Kristian Reich sold 50,000 shares of company stock on June 17, 2026, at an average price of $19.43 under a pre-arranged Rule 10b5-1 trading plan.
- ▪MoonLake Immunotherapeutics CEO Da Silva Jorge Santos sold 68,289 shares of company stock on July 10, 2026, at an average price of $20.02 under a pre-arranged Rule 10b5-1 trading plan.
- ▪MoonLake Immunotherapeutics insiders made 20 reported stock sales and zero purchases over the six months preceding August 10, 2026, including transactions by the CEO, CSO, and CFO.
Story comments
Loading comments…